About Daxor
Daxor is a publicly listed company based in New York (United States) founded in 1970. Blood volume analyzers are developed by Daxor for diagnostic applications. Daxor offers products and services including BVA-100. Its focus areas include Life Sciences, Hematology, In Vitro Diagnostics Tests and Blood Analyzer. Its legal entity is DAXOR CORPORATION. Its competitors include Cellmic, Essenlix and RizLab Health; 3 of its 3 listed competitors have raised funding.
Company details
Daxor was founded in 1970 in New York, United States, and operates in the medical device sector. The BVA-100 blood volume analyzer is produced by the company, with measurements completed in under 60 minutes. This tool is utilized to assess blood volume and support treatment decisions for conditions including congestive heart failure, anemia, hypertension, and dialysis needs. Operations focus on healthcare diagnostics across the United States.
- Annual Revenue$503.42 K (USD)as on Dec 31, 2025
- Net Profit$9.17 M (USD)1609.71as on Dec 31, 2025
- EBITDA$9.19 M (USD)1378.18as on Dec 31, 2025
- Latest Funding Round$305K (USD), Grant
Sep 2023
- InvestorsHHS
& 1 more
Products & Services of Daxor
Daxor offers a comprehensive portfolio of products and services, including BVA-100.
Device for accurate blood volume measurement in medical diagnostics.
Funding Insights of Daxor
- Total Rounds 4
- Last Round Grant — $305,000
- First Round $7M
(Jul 2020)
- Investors Count 2
All 4 funding rounds of Daxor with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
2 investors in total: 2 institutional.
Investors in Daxor
Daxor has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include HHS and National Institute of General Medical Sciences.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Basic research is supported to advance medical sciences. | nigms.nih.gov | Bethesda, United States | ||
Public health and human services are overseen by HHS. | 1953 | hhs.gov |
Investor details for Daxor
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Daxor
17 people are tracked at Daxor (8 in leadership, 5 in board & advisors, 4 in team).
| Name | Role | Group |
|---|---|---|
Jonathan Feldschuh | Chief Scientific Officer | Leadership |
Kathryn A. Kornafel | Sr. VP Marketing & Commercial Development | Leadership |
Robert J. Michel | CFO | Leadership |
Michael Feldschuh | President & CEO | Leadership |
J.p. Bryant | National Sales Director West | Leadership |
John Jefferies | Chief Medical Officer | Leadership |
Linda Cooper | Vice President Development & Operations | Leadership |
Shawn Urban | Director Of Software Engineering | Leadership |
Caleb Desrosiers | Director | Board & advisors |
Edward S. Feuer | Director | Board & advisors |
James A. Lombard | Director | Board & advisors |
Joy Goudie | Director | Board & advisors |
Henry D. Cremisi | Director | Board & advisors |
John Ciolkosz | Data Scientist | Team |
Marc Silver | Medical Advisor | Team |
Laura Keith | Strategic Account Sales Manager | Team |
Eric Edwards | Technical Applications Manager | Team |
Complete people profiles for Daxor
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Daxor
Daxor is a publicly listed company on the NASDAQ with ticker symbol DXR in USA, operating in the Miscellaneous sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date06 Apr 1992
- Listed onNASDAQ: DXR
- Listed entityDaxor Corporation
- Exchange sectorMiscellaneous
- ISINUS2394671034
- Share price$10.35 (+0.45% on the day) · 2026-10-13
- Market capitalisation$60.4M
- Price to earnings8.5
- EPS (diluted, trailing year)$1.22
- Volume (last session)19,572
Financials of Daxor
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $503,420 | $9.2M | $9.2M |
| 2024 | -$135,670 | $536,330 | $621,420 |
| 2023 | $34.6M | $280,640 | $329,740 |
| 2022 | -$353,360 | $5.2M | $5.2M |
| 2021 | -$2.6M | $4.8M | $4.8M |
Detailed financial statements for Daxor
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Daxor
4 dated milestones of Daxor across 53 years, from founding to its latest funding, stage changes and deals.
- Founded Daxor is founded.
- IPO Lists on the stock exchange (IPO).
- Funding First funding round of $7.0M.
- Funding Latest funding round, Grant, of $305K.
Competitors of Daxor
Daxor has 3 listed competitors in our database, 3 of them funded. They include Cellmic, Essenlix and RizLab Health.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| cellmic.com | 2009 | Los Angeles, United States | $5M | Rapid test readers are developed for chromatographic and fluorescent assays. | ||
| essenlix.com | 2013 | Monmouth Junction, United States | $20M | Mobile health self-test platform is provided using nanotechnology and AI. | ||
| rizlabhealth.com | 2018 | Princeton, United States | $250,000 | An AI-based device for complete blood count analysis is developed. |
Detailed competitors of Daxor
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Daxor
The website of Daxor (daxor.com) receives about 3.5K visits a month.
- Monthly visits3.5K
▼ 19.6% vs previous month
Websites whose visitors overlap most with Daxor. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
thrombocyte.com | thrombocyte.com | 100% | – | ||
medicacorp.com | medicacorp.com | 100% | #4,885,435 | – | |
| haemonetics.com | 99% | 50.5K | #632,767 | View details | |
nps.org.au | nps.org.au | 99% | #72,858 | – | |
| medicregister.com | 99% | #8,455,269 | View details | ||
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 11 similar websites and full traffic analytics for Daxor
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 11 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Hematology
3 companies that operate in the same segment as Daxor (Hematology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Catheter-based thrombectomy devices for vascular emboli removal are developed. | 2011 | Irvine, California, United States | USD 51.89 M | USD 493.63 M | 696 | |
Small molecules are developed to treat hematologic and musculoskeletal disorders. | 2016 | Lexington, Kentucky, United States | USD 90 M | USD 244.06 M | 169 | |
Developer of Allogeneic cell therapy for cancer, autoimmune diseases and genetic blood disorders | 2016 | Menlo Park, California, United States | USD 300 M | 384 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Daxor
Complete news archive for Daxor
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Daxor
Daxor was founded in 1970 and raised its 1st funding round 50 years after it was founded.
Daxor is headquartered in New York, United States. It is registered at New York, New York, United States.
Annual revenue of Daxor is $503.42K as on Dec 31, 2025.
Daxor was founded in 1970 in New York, United States, and operates in the medical device sector. The BVA-100 blood volume analyzer is produced by the company, with measurements completed in under 60 minutes. This tool is utilized to assess blood volume and support treatment decisions for conditions including congestive heart failure, anemia, hypertension, and dialysis needs. Operations focus on healthcare diagnostics across the United States.
Daxor's top competitors include Cellmic, Essenlix and RizLab Health.
Daxor offers BVA-100.
Yes, Daxor is publicly traded on NASDAQ under the ticker symbol DXR.
Daxor has 2 investors. Key investors include HHS, and National Institute of General Medical Sciences.
Daxor operates through Daxor Corporation.